Osilodrostat
AssetAlso called LCI699, Isturisa, LCI-699-NX, LCI699-AZA
Aldosterone synthase (CYP11B2) inhibitor
- Stage
- Approved
- Modality
- Small molecule
- Target
- CYP11B1
- 5
- Indications
- 4
- Trials
- 4
- Developers
Indications
6No named disease
Approved, open.fda.gov, Mar 6, 2020
Hypertension
Phase 3, Recruiting, NCT07247162, clinicaltrials.gov, Oct 28, 2026
Cushing's syndrome
Phase 3, Recruiting, NCT07247162, clinicaltrials.gov, Oct 28, 2026
3 more
In the full profile
- Target and mechanism1
- Owner and partners4
- Trials4
- Evidence for its targets2
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.